Melanoma Res 2021 Apr 12. Epub 2021 Apr 12.
Department of Health Technology Assessment, Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam Department of Epidemiology and Biostatistics, Amsterdam UMC, Amsterdam Department of Internal Medicine, Northwest Clinics, Alkmaar Department for Medical Oncology, Erasmus MC Cancer Institute, Rotterdam Department of Surgical Oncology, Albert Schweitzer Hospital, Dordrecht Department of Dermatology, Tergooi, Hilversum Department of Internal Medicine, Amphia Hospital, Breda Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, the Netherlands.
The aim of this study was to provide insight into real-world healthcare costs of patients initially diagnosed with localized or regionally advanced melanoma in three Dutch hospitals between 2003 and 2011. Patients were stratified according to their stage at diagnosis and recurrence status. Costs were calculated by applying unit costs to individual patient resource use and reported for the full disease course, the initial treatment episode, and treatment episodes for disease recurrence (stratified by type of recurrence). Read More